Variant rs9929218 Linked with Prognosis of Patients with CRC
the Cancer Therapy Advisor take:
Patients with stage 4 colorectal cancer (CRC) who have the variant rs9929218 at 16q22 (intron 2 of CDH1, encoding E-cadherin) are at an increased risk for worse survival and poor response to chemotherapy, according to an article published online in the journal Clinical Cancer Research.
Initially, the authors analyzed 20 single-nucleotide polymorphism (SNPs) associated with risk of CRC from 14 genome-wide loci and how they affected the prognosis of 2,083 patients with CRC.
Secondly, three SNPs were analyzed from an independent group of 5,552 patients with advanced stage CRC.
Results showed three variants in the training phase were associated with patient survival. However, only one variant (rs9929218) had a significant association in the validation phase.
Patients who were homozygous for the minor allele, especially those with stage 4 cancer (P=2.7 x 10-5), were observed to have worse survival (training phase HR, 1.43; 95% CI: 1.20, 1.71; P=5.8 × 10−5; validation phase; HR, 1.18; 95% CI: 1.01, 1.37; P=3.2 × 10−2; combined HR, 1.28; 95% CI: 1.14, 1.43; P=2.2 × 10−5).
Furthermore, a significant correlation was observed between the variant rs9929218 and a negative response to chemotherapy (P=3.9 x 10-4).
The study suggests that these findings provide a mechanism underlying rs9929218’s potential in making a patient prognosis.
Patients with colorectal cancer who have the variant rs9929218 at 16q22 are at an increased risk for worse survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy